• Explore /
  • Poster
  • / A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

Daniel Costin Danila

Daniel Costin Danila

Memorial Sloan Kettering Cancer Center, New York, NY

Daniel Costin Danila , David Michael Waterhouse , Leonard Joseph Appleman , David William Pook , Nobuaki Matsubara , Tanya B. Dorff , Jae-Lyun Lee , Andrew J. Armstrong , Miso Kim , Lisa Horvath , Christopher Joseph Sumey , Freda Cooner , Mark Salvati , Julia Stieglmaier , William Kevin Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04221542

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5101)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5101

Abstract #

TPS5101

Poster Bd #

280a

Abstract Disclosures

Similar Posters

First Author: William Kevin Kelly

First Author: W. Kevin Kelly

First Author: Elena Castro

First Author: Stephen J. Freedland